Jiangsu Hengrui Pharmaceuticals Co.,Ltd
1276.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$318.59B
Close$
$31.92
31.6% downside
Current Fair Value
31.6% downsideOvervalued by 31.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $318.59 Billion |
|---|---|
| Enterprise Value | $281.52 Billion |
| Dividend Yield | $0.23 (0.43%) |
| Earnings per Share | $1.32 |
| Beta | 0.12 |
| Outstanding Shares | 6,600,538,185 |
Return
| Return on Equity | 11.99% |
|---|---|
| Return on Assets | 10.92% |
| Return on Invested Capital | 11.77% |
Valuation & Multiples
| P/E Ratio | 39.7 |
|---|---|
| PEG | -260.33 |
| Price to Sales | 11.67 |
| Price to Book Ratio | 5.18 |
| Enterprise Value to Revenue | 8.99 |
| Enterprise Value to EBIT | 35.96 |
| Enterprise Value to Net Income | 36 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 23, 2026
EPS Estimate
$0.40
Average shareholder expectationRevenue Estimate
$10.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd
20,602 employees
CEO: Sun Piaoyang Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas...